Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Pablo Borrega García
Observed name:
Pablo Borrega Garcia
Institution:
Complejo Hospitalario de Cáceres
Observed institutions:
Hospital San Pedro de Alcántara,
Complejo Hospitalario de Cáceres
OpenAlex ID:
A5113937544
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
2024
·
Robert J. Motzer
, Camillo Porta
, et al.
·
Journal of Clinical Oncology
·
222
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
2024
·
Fred Saad
, Egils Vjaters
, et al.
·
Journal of Clinical Oncology
·
199
Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study
2019
·
Luis Manso
, Fernando Moreno Antón
, et al.
·
The Breast Journal
·
9
PDF
Prognostic value of the TGFβ1 rs4803455 single nucleotide polymorphism in small cell lung cancer
2020
·
Pablo Ayala de Miguel
, María Valle Enguix-Riego
, et al.
·
Tumori Journal
·
6
Increased Quality of Life in Patients with Breakthrough Cancer Pain after Individualized Therapy: the CAVIDIOM Study
2022
·
Paula González Villarroel
, Josep Gumà Padró
, et al.
·
Future Oncology
·
5
Extreme elevation of acute phase reactants and shock secondary to dabrafenib–trametinib
2021
·
Pablo Ayala de Miguel
, Itziar Gorospe García
, et al.
·
Melanoma Research
·
3
Hyperprogressive disease during treatment with immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC).
2020
·
Pablo Ayala de Miguel
, Javier López Gallego
, et al.
·
Journal of Clinical Oncology
·
3
Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy
2024
·
Lucia Osorio
, Tatiana P. Grazioso
, et al.
·
Clinical & Translational Oncology
·
2
Immune-related adverse events and outcomes during treatment with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) patients.
2020
·
Javier López Gallego
, Pablo Ayala de Miguel
, et al.
·
Journal of Clinical Oncology
·
1
Otros tumores: sarcoma y melanoma cutáneo
2007
·
Helena López de Ceballos Reyna
, M. Díaz Martín
, et al.
·
Dialnet (Universidad de la Rioja)
·
1
Show more works
View as search
Works count:
10
Citation count:
451
H-index:
5
I10-index:
2
Year
Topic
Type